BackCuranex PharmaceuticalsCommon Stock Overview

Curanex PharmaceuticalsCommon Stock Total Liabilities

Latest total liabilities for CURX: $330K.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$332644.00
21.02% YoYΔ $-88519.00 vs prior year quarter

Peer average

Loading

Curanex PharmaceuticalsCommon Stock Total Liabilities History

Loading

Curanex PharmaceuticalsCommon Stock vs. peers: Total Liabilities Comparison

Loading

Curanex PharmaceuticalsCommon Stock Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Curanex PharmaceuticalsCommon Stock (CURX) FAQ

As of the most recent data (March 2026), CURX shows a total liabilities of $330K. That compares with $420K in the prior-year period — down 21.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CURX's total liabilities is now $330K (was $420K) — a 21.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Curanex PharmaceuticalsCommon Stock is outperforming or lagging.

Tracking CURX's total liabilities over time shows whether Curanex PharmaceuticalsCommon Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $330K That compares with $420K in the prior-year period — down 21.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Curanex PharmaceuticalsCommon Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $330K) with ownership activity and broader fundamentals.

Curanex PharmaceuticalsCommon Stock's total liabilities is $330K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.